2009-12-22 00:23:09 -
Research and Markets ( www.researchandmarkets.com/research/5577e0/pharmadeal_financi : 
) has announced the addition of the " PharmaDeal Financials Oncology : " database table to their offering.
Early stage deals count for almost 45% of all oncology deals during the 13-year period covering 226 licensing deals in the PharmaDeal Financials Oncology : database. Of the 221 companies included in
the database, Exelixis leads the rank of licensors both in number of early stage deals and in the total number of licensing deals established.
Novartis, GlaxoSmithKline, Roche and its recently acquired Genentech belong to the top licensees with regard to the number of deals closed.
Around 50% of the deals established by the latter are antibody-related.
Antibody-related licenses remain popular and count for 24% of all licensing deals closed. Vaccines were also a popular licensing target.
In around 10% co-development alliances were set up. Co-promotion rights by licensors were obtained in more than 20%, remarkably also if the license only covered certain countries. Potential deal sizes and upfront payments by big pharma to different licensors were found to vary 100% or more for similar compound classes in preclinical development. Compound value creation did show to have an effect on potential deal sizes, one of the best examples being NeoTherapeutics' platinum compound, which was sublicensed by GPC Biotech to Pharmion Corporation.
Selected indications
Bile duct tumors, bladder cancer, brain tumors, breast cancer, cervical cancer, colon cancer, colorectal cancer, esophageal cancer, gastric cancer, glioblastoma, head & neck cancer, hepatocellular carcinoma, leukemia's, lung cancer, lymphoma's, melanoma, mesothelioma, multiple myeloma, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, sarcoma, thyroid cancer
Selected compound keywords
Adnectins, angiogenesis inhibitors, anthracyclines, antibodies, antisense, aptamers, (aurora) kinase inhibitors, cytokines, HDAC inhibitors, hedgehog signaling pathway inhibitors, MEK-inhibitors, mTOR inhibitors, nanobodies, nucleoside analogues, platinum compounds, siRNA, taxanes, topoisomerase inhibitors, TLR-agonists, tumor activated prodrugs, tyrosine kinase inhibitors, vaccines, vascular disrupting agents, VEGF inhibitors
PharmaDeal Financials databases
PharmaDeal Financials are unique searchable thematic licensing databases, which offer quick and affordable access to financial information on therapeutic license deals.
The databases focus on financial deal specifics (as far as available) for therapeutics over the last 13 years, including potential deal size, upfront, milestone payments, royalties on sales, research funding and equity.
The databases can be installed directly on your computer and are searchable by licensor, licensee, disease area, indication, compound details, compound name, development stage (research - filed for regulatory approval), geographical territory, all financial deal specifics mentioned and by year of deal establishment or any combination thereof.
System requirements: Windows 2000 / XP / Vista
Companies Mentioned.
- 3M Corporation
- Abbott Laboratories
- Ablynx
- Access Oncology
- Adherex Technologies
- Adnexus
- Advancell
- Avant Immunotherapeutics (incl. Celldex Therapeutics)
- Agensys
- Alfacell Corporation
- Allergan
- Alnylam Pharmaceuticals
- AltaRex Corporation
- American Bioscience
- Amgen (incl. Abgenix, Tularik)
- Anges MG
- Anthra Pharmaceuticals
- Antisoma
- Aphton Corporation
- Archemix Corporation
- Ariad Pharmaceuticals
- Arius Research
- Arqule
- Array Biopharma
- Astellas Pharma
- Astex Therapeutics
- AstraZeneca (incl. Cambridge Antibody Technology Zeneca)
- + many more
For more information visit
www.researchandmarkets.com/research/5577e0/pharmadeal_financi :
Research and MarketsLaura Wood, Senior Manager,
press@researchandmarkets.com : mailto:press@researchandmarkets.com U.S.
Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
